Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965203 | 1.00 | L3MBTL1 (0.61) | L3MBTL1HTR6KAT6AACLYSLC40A1 | |
| Choline SCHEMBL21617610 | 0.83 | L3MBTL1 (0.46) | L3MBTL1HTR6KAT6AACLYSLC40A1 | |
| SCHEMBL3555416 | 0.83 | L3MBTL1 (0.51) | L3MBTL1HTR6SLC40A1TSHRCA12 | |
| SCHEMBL28146309 | 0.82 | HTR6 (0.55) | HTR6KAT6AACLYSLC40A1SLC22A12 | |
| SCHEMBL29288590 | 0.82 | HTR6 (0.55) | HTR6KAT6AACLYSLC40A1SLC22A12 | |
| SCHEMBL28146316 | 0.82 | HTR6 (0.55) | HTR6KAT6AACLYSLC40A1SLC22A12 | |
| SCHEMBL28844042 | 0.82 | HTR6 (0.55) | HTR6KAT6AACLYSLC40A1SLC22A12 | |
| SCHEMBL5501632 | 0.82 | HTR6 (0.55) | HTR6KAT6AACLYSLC40A1SLC22A12 | |
| SCHEMBL2371547 | 0.82 | HTR6 (0.55) | HTR6KAT6AACLYSLC40A1SLC22A12 | |
| SCHEMBL8224006 | 0.82 | HTR6 (0.55) | HTR6KAT6AACLYSLC40A1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547204-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer Intellectual Property GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | claimed |
| WO-2011113861-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | WO | claimed |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3897637-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3820573-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | Novartis AG (CH) | 2021-05-19 | — | — | EP | disclosed |
| EP-3820574-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | Novartis AG (CH) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020128972-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020012337-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020012334-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011113861-A2 | ARYL AND HETARYL SULFONAMIDES AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | WO | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | L3MBTL1 3073/4885HTR6 550/4885KAT6A 3365/4885 |
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | L3MBTL1 1818/4885HTR6 3593/4885KAT6A 3976/4885 |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | STS, ARSA, TST | L3MBTL1 3916/4885HTR6 1828/4885KAT6A 2457/4885 |
| US-20100240680-A1 | Purine derivatives as a2a agonists | ADORA2A, ADORA1, ADORA3 | L3MBTL1 4045/4885HTR6 208/4885KAT6A 4803/4885 |
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | L3MBTL1 4878/4885HTR6 54/4885KAT6A 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.